dual glp-1/gip agonist GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes Effects of tirzepatide, a dual

Multiple head-to-head trials demonstrate 15-20% body weight reduction with tirzepatide at therapeutic doses versus 10-15% with semaglutide

Key products such as Ozempic , Wegovy , Mounjaro , and Zepbound have gained household name status, driven by aggressive marketing, strong clinical data, and high-profile endorsements

When patients come into my office asking for help with their weight loss medication affordability, with a monthly price around $5, its not difficult to convince the patient to try phentermine to continue working toward their weight loss goal. The unique insight derived from Scripta's AI technology highlights the real-world transitions occurring among patients, revealing this Wegovy to phentermine switch, a top 20 book-of-business switch that is reshaping the narrative of obesity care

Rodbard HW, Rosenstock J, Canani LH, et al

[DOI] [PMC free article] [PubMed] [Google Scholar] 40.Pediatric Endocrine Society Obesity Committee

Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people